Neisseria meningitidis native outer membrane vesicles containing different lipopolysaccharide glycoforms as adjuvants for meningococcal and nonmeningococcal antigens

Clinical and Vaccine Immunology

Volumn 21, Issue 2, 2014, Pages 234-242

  Nagaputra, Jerry C ^a   Rollier, Christine S ^a   Sadarangani, Manish ^a   Hoe, J Claire ^a   Mehta, Ojas Hrakesh ^a   Norheim, Gunnstein ^a   Saleem, Muhammad ^b   Chan, Hannah ^c   Derrick, Jeremy P ^b   Feavers, Ian ^c   Pollard, Andrew J ^a   Moxon, E Richard ^d  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^d CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BLOOD BACTERICIDAL ACTIVITY; CELL-DERIVED MICROPARTICLES; CELLS, CULTURED; DENDRITIC CELLS; DRUG CARRIERS; HUMANS; IMMUNOGLOBULIN G; LIPOPOLYSACCHARIDES; MICE; NEISSERIA MENINGITIDIS;

EID: 84893322643     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00561-13     Document Type: Article

References (62)

1. Brunelli B, Del Tordello E, Palumbo E, Biolchi A, Bambini S, Comanducci M, Muzzi A, Pizza M, Rappuoli R, Donnelly JJ, Giuliani MM, Serruto D. 2011. Influence of sequence variability on bactericidal activity sera induced by Factor H binding protein variant 1.1. Vaccine 29:1072-1081. http://dx.doi.org/ 10.1016/j.vaccine.2010.11.064.
2. Cartwright K, Noah N, Peltola H, Meningococcal Disease Advisory Board. 2001. Meningococcal disease in Europe: epidemiology, mortality, and prevention with conjugate vaccines. Report of a European advisory board meeting Vienna, Austria, 6-8 October, 2000. Vaccine 19:4347-4356. http://dx.doi.org/10.1016/ S0264-410X(01)00205-5. (Pubitemid 32718655)
3. Finne J, Leinonen M, Mäkelä PH. 1983. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 2:355-357. (Pubitemid 13028927)
4. Fries LF, Gordon DM, Richards RL, Egan JE, Hollingdale MR, Gross M, Silverman C, Alving CR. 1992. Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy. Proc. Natl. Acad. Sci. U. S. A. 89:358-362. http://dx.doi.org/10.1073/pnas.89.1.358.
5. Giuliani MM, Adu-Bobie J, Comanducci M, Aricò B, Savino S, Santini L, Brunelli B, Bambini S, Biolchi A, Capecchi B, Cartocci E, Ciucchi L, Di Marcello F, Ferlicca F, Galli B, Luzzi E, Masignani V, Serruto D, Veggi D, Contorni M, Morandi M, Bartalesi A, Cinotti V, Mannucci D, Titta F, Ovidi E, Welsch JA, Granoff D, Rappuoli R, Pizza M. 2006. A universal vaccine for serogroup B meningococcus. Proc. Natl. Acad. Sci. U. S. A. 103:10834-10839. http://dx.doi.org/10.1073/pnas.0603940103. (Pubitemid 44148381)
6. Ruijne N, Lea RA, O'Hallahan J, Oster P, Martin D. 2006. Understanding the immune responses to the meningococcal strain-specific vaccine MeNZB measured in studies of infants. Clin. Vaccine Immunol. 13:797-801. http://dx.doi.org/10. 1128/CVI.00038-06.
7. Sierra GV, Campa HC, Varcacel NM, Garcia IL, Izquierdo PL, Sotolongo PF, Casanueva GV, Rico CO, Rodriguez CR, Terry MH. 1991. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. 14:195-207; discussion 208-110.
8. Gorringe AR, Pajón R. 2012. Bexsero: a multicomponent vaccine for prevention of meningococcal disease. Hum. Vaccin. Immunother. 8:174-183. http://dx.doi.org/10.4161/hv.18500.
9. Tappero JW, Lagos R, Ballesteros AM, Plikaytis B, Williams D, Dykes J, Gheesling LL, Carlone GM, Høiby EA, Holst J, Nøkleby H, Rosenqvist E, Sierra G, Campa C, Sotolongo F, Vega J, Garcia J, Herrera P, Poolman JT, Perkins BA. 1999. Immunogenicity of 2 serogroup B outermembrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 281:1520-1527. (Pubitemid 29200936)
10. Verheul AF, Van Gaans JA, Wiertz EJ, Snippe H, Verhoef J, Poolman JT. 1993. Meningococcal lipopolysaccharide (LPS)-derived oligosaccharide-protein conjugates evoke outer membrane protein- but not LPS-specific bactericidal antibodies in mice: influence of adjuvants. Infect. Immun. 61:187-196. (Pubitemid 23015416)
11. MacLeod MK, McKee AS, David A, Wang J, Mason R, Kappler JW, Marrack P. 2011. Vaccine adjuvants aluminum and monophosphoryl lipid A provide distinct signals to generate protective cytotoxic memory CD8 T cells. Proc. Natl. Acad. Sci. U. S. A. 108:7914-7919. http://dx.doi.org/10.1073/pnas.1104588108.
12. Rappuoli R, Mandl CW, Black S, De Gregorio E. 2011. Vaccines for the twenty-first century society. Nat. Rev. Immunol. 11:865-872. http://dx.doi.org/10.1038/nri3085.
13. Moingeon P, Haensler J, Lindberg A. 2001. Towards the rational design of Th1 adjuvants. Vaccine 19:4363-4372. http://dx.doi.org/10.1016/S0264-410X(01) 00193-1. (Pubitemid 32718658)
14. Holst J, Martin D, Arnold R, Huergo CC, Oster P, O'Hallahan J, Rosenqvist E. 2009. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 27(Suppl 2):B3-B12. http://dx.doi.org/10.1016/j.vaccine.2009.04.071.
15. Rosenqvist E, Høiby EA, Bjune G, Aase A, Halstensen A, Lehmann AK, Paulssen J, Holst J, Michaelsen TE, Nøkleby H, Frøholm LO, Closs O. 1998. Effect of aluminium hydroxide and meningococcal serogroup C capsular polysaccharide on the immunogenicity and reactogenicity of a group B Neisseria meningitidis outer membrane vesicle vaccine. Dev. Biol. Stand. 92:323-333.
16. Keiser PB, Biggs-Cicatelli S, Moran EE, Schmiel DH, Pinto VB, Burden RE, Miller LB, Moon JE, Bowden RA, Cummings JF, Zollinger WD. 2011. A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, overexpressed factor H binding protein, two PorAs and stabilized OpcA expression. Vaccine 29:1413-1420. http://dx.doi.org/ 10.1016/j.vaccine.2010.12.039.
17. Jäkel A, Plested JS, Hoe JC, Makepeace K, Gidney MA, Lacelle S, St Michael F, Cox AD, Richards JC, Moxon ER. 2008. Naturally-occurring human serum antibodies to inner core lipopolysaccharide epitopes of Neisseria meningitidis protect against invasive meningococcal disease caused by isolates displaying homologous inner core structures. Vaccine 26:6655-6663. http://dx.doi.org/10. 1016/j.vaccine.2008.09.041.
18. Plested JS, Harris SL, Wright JC, Coull PA, Makepeace K, Gidney MA, Brisson JR, Richards JC, Granoff DM, Moxon ER. 2003. Highly conserved Neisseria meningitidis inner-core lipopolysaccharide epitope confers protection against experimental meningococcal bacteremia. J. Infect. Dis. 187:1223-1234. http://dx.doi.org/10.1086/368360. (Pubitemid 36438962)
19. Plested JS, Makepeace K, Jennings MP, Gidney MA, Lacelle S, Brisson J, Cox AD, Martin A, Bird AG, Tang CM, Mackinnon FM, Richards JC, Moxon ER. 1999. Conservation and accessibility of an inner core lipopolysaccharide epitope of Neisseria meningitidis. Infect. Immun. 67:5417-5426. (Pubitemid 29455320)
20. Beutler B, Rietschel ET. 2003. Innate immune sensing and its roots: the story of endotoxin. Nat. Rev. Immunol. 3:169-176. http://dx.doi.org/10.1038/ nri1004. (Pubitemid 37328694)
21. Naess LM, Aarvak T, Aase A, Oftung F, Høiby EA, Sandin R, Michaelsen TE. 1999.HumanIgG subclass responses in relation to serum bactericidal and opsonic activities after immunization with three doses of the Norwegian serogroup B meningococcal outer membrane vesicle vaccine. Vaccine 17:754-764. http://dx.doi.org/10.1016/S0264-410X(98)00259-X. (Pubitemid 29074728)
22. van der Ley P, Steeghs L, Hamstra HJ, ten Hove J, Zomer B, van Alphen L. 2001. Modification of lipid A biosynthesis in Neisseria meningitidis lpxL mutants: influence on lipopolysaccharide structure, toxicity, and adjuvant activity. Infect. Immun. 69:5981-5990. http://dx.doi.org/10.1128/IAI.69.10.5981- 5990.2001. (Pubitemid 32885156)
23. Zhang P, Snyder S, Feng P, Azadi P, Zhang S, Bulgheresi S, Sanderson KE, He J, Klena J, Chen T. 2006. Role of N-acetylglucosamine within core lipopolysaccharide of several species of gram-negative bacteria in targeting the DC-SIGN (CD209). J. Immunol. 177:4002-4011. (Pubitemid 44359933)
24. Steeghs L, van Vliet SJ, Uronen-Hansson H, van Mourik A, Engering A, Sanchez-Hernandez M, Klein N, Callard R, van Putten JP, van der Ley P, van Kooyk Y, van de Winkel JG. 2006. Neisseria meningitidis expressing lgtB lipopolysaccharide targets DC-SIGN and modulates dendritic cell function. Cell. Microbiol. 8:316-325. http://dx.doi.org/10.1111/j.1462-5822.2005.00623.x. (Pubitemid 43356053)
25. Jennings MP, Hood DW, Peak IR, Virji M, Moxon ER. 1995. Molecular analysis of a locus for the biosynthesis and phase-variable expression of the lacto-N-neotetraose terminal lipopolysaccharide structure in Neisseria meningitidis. Mol. Microbiol. 18:729-740. http://dx.doi.org/10.1111/j.1365-2958. 1995.mmi-18040729.x. (Pubitemid 26008845)
26. Borrow R, Aaberge IS, Santos GF, Eudey TL, Oster P, Glennie A, Findlow J, Høiby EA, Rosenqvist E, Balmer P, Martin D. 2005. Interlaboratory standardization of the measurement of serum bactericidal activity by usinghumancomplementagainst meningococcal serogroup b, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine. Clin. Diagn. Lab. Immunol. 12:970-976. http://dx.doi.org/10.1128/CDLI.12.8.970- 976.2005.
27. Criss AK, Kline KA, Seifert HS. 2005. The frequency and rate of pilin antigenic variation in Neisseria gonorrhoeae. Mol. Microbiol. 58:510-519. http://dx.doi.org/10.1111/j.1365-2958.2005.04838.x. (Pubitemid 41476165)
28. Gunn JS, Stein DC. 1996. Use of a non-selective transformation technique to construct a multiply restriction/modification-deficient mutant of Neisseria gonorrhoeae. Mol. Gen. Genet. 251:509-517. http://dx.doi.org/10.1007/BF02173639.
29. Sadarangani M, Hoe JC, Callaghan MJ, Jones C, Chan H, Makepeace K, Daniels-Treffandier H, Deadman ME, Bayliss C, Feavers I, Van der Ley P, Pollard AJ. 2012. Construction of Opa-positive and Opa-negative strains of Neisseria meningitidis to evaluate a novel meningococcal vaccine. PLoS One 7:e51045. http://dx.doi.org/10.1371/journal.pone.0051045.
30. Zollinger WD, Mandrell RE, Griffiss JM, Altieri P, Berman S. 1979. Complex of meningococcal group B polysaccharide and type 2 outer membrane protein immunogenic in man. J. Clin. Invest. 63:836-848. http://dx.doi.org/10. 1172/JCI109383. (Pubitemid 9182533)
31. Vipond C, Wheeler JX, Jones C, Feavers IM, Suker J. 2005. Characterization of the protein content of a meningococcal outer membrane vesicle vaccine by polyacrylamide gel electrophoresis and mass spectrometry. Hum. Vaccin. 1:80-84. http://dx.doi.org/10.4161/hv.1.2.1651.
32. Lesse AJ, Campagnari AA, Bittner WE, Apicella MA. 1990. Increased resolution of lipopolysaccharides and lipooligosaccharides utilizing tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis. J. Immunol. Methods 126:109-117. http://dx.doi.org/10.1016/0022-1759(90)90018-Q. (Pubitemid 20041434)
33. Saleem M, Moore J, Derrick JP. 2012. Expression, purification, and crystallization of neisserial outer membrane proteins. Methods Mol. Biol. 799:91-106. http://dx.doi.org/10.1007/978-1-61779-346-2-6.
34. Manghi MA, Pasetti MF, Brero ML, Deluchi S, di Paola G, Mathet V, Eriksson PV. 1994. Development of an ELISA for measuring the activity of tetanus toxoid in vaccines and comparison with the toxin neutralization test in mice. J. Immunol. Methods 168:17-24. http://dx.doi.org/10.1016/0022-1759(94)90204-6.
35. Plikaytis BD, Turner SH, Gheesling LL, Carlone GM. 1991. Comparisons of standard curve-fitting methods to quantitate Neisseria meningitidis group A polysaccharide antibody levels by enzyme-linked immunosorbent assay. J. Clin. Microbiol. 29:1439-1446.
36. Borrow R, Carlone GM. 2001. Serogroup B and C serum bactericidal assays, p 289-304. In Pollard AJ, Maiden MC (ed), Meningococcal vaccines. Methods and protocols. Humana Press, Inc., Totowa, New Jersey.
37. Giuliani MM, Biolchi A, Serruto D, Ferlicca F, Vienken K, Oster P, Rappuoli R, Pizza M, Donnelly J. 2010. Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus. Vaccine 28:5023-5030. http://dx.doi.org/10.1016/j.vaccine.2010.05.014.
38. Coffman RL, Seymour BW, Lebman DA, Hiraki DD, Christiansen JA, Shrader B, Cherwinski HM, Savelkoul HF, Finkelman FD, Bond MW. 1988. The role of helper T cell products in mouse B cell differentiation and isotype regulation. Immunol. Rev. 102:5-28. http://dx.doi.org/10.1111/j.1600-065X.1988.tb00739.x. (Pubitemid 18095718)
39. DeKruyff RH, Mosmann RR, Umetsu DT. 1990. Induction of antibody synthesis by CD4+ T cells: IL 5 is essential for induction of antigen-specific antibody responses by TH2 but not TH1 clones. Eur. J. Immunol. 20:2219-2227. http://dx.doi.org/10.1002/eji.1830201010. (Pubitemid 20368206)
40. Wedege E, Dalseg R, Caugant DA, Poolman JT, Frøholm LO. 1993. Expression of an inaccessible P1.7 subtype epitope on meningococcal class 1 proteins. J. Med. Microbiol. 38:23-28. http://dx.doi.org/10.1099/00222615-38-1- 23. (Pubitemid 23025177)
41. Steinhagen F, Kinjo T, Bode C, Klinman DM. 2011. TLR-based immune adjuvants. Vaccine 29:3341-3355. http://dx.doi.org/10.1016/j.vaccine.2010.08. 002.
42. GlaxoSmithKline Vaccine HPV-007 Study Group, Romanowski B, de Borba PC, Naud PS, Roteli-Martins CM, De Carvalho NS, Teixeira JC, Aoki F, Ramjattan B, Shier RM, Somani R, Barbier S, Blatter MM, Chambers C, Ferris D, Gall SA, Guerra FA, Harper DM, Hedrick JA, Henry DC, Korn AP, Kroll R, Moscicki AB, Rosenfeld WD, Sullivan BJ, Thoming CS, Tyring SK, Wheeler CM, Dubin G, Schuind A, Zahaf T, Greenacre M, Sgriobhadair A. 2009. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 374:1975-1985. http://dx.doi.org/10.1016/S0140-6736(09)61567-1.
43. Vandepapelière P, Horsmans Y, Moris P, Van Mechelen M, Janssens M, Koutsoukos M, Van Belle P, Clement F, Hanon E, Wettendorff M, Garçon N, Leroux-Roels G. 2008. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vaccine 26:1375-1386. http://dx.doi.org/10.1016/j.vaccine.2007.12.038.
44. Sieling PA, Chung W, Duong BT, Godowski PJ, Modlin RL. 2003. Toll-like receptor 2 ligands as adjuvants for human Th1 responses. J. Immunol. 170:194-200. (Pubitemid 36026140)
45. Beninati C, Midiri A, Mancuso G, Biondo C, Arigò M, Gerace E, Papasergi S, Gambuzza M, Boretti M, Magliani W, Conti S, Polonelli L, Teti G. 2006. Antiidiotypic DNA vaccination induces serum bactericidal activity and protection against group B meningococci. J. Exp. Med. 203:111-118. http://dx.doi.org/10.1084/jem.20051540. (Pubitemid 43139650)
46. Borrow R, Richmond P, Kaczmarski EB, Iverson A, Martin SL, Findlow J, Acuna M, Longworth E, O'Connor R, Paul J, Miller E. 2000. Meningococcal serogroup C-specific IgG antibody responses and serum bactericidal titres in children following vaccination with a meningococcal A/C polysaccharide vaccine.FEMSImmunol. Med. Microbiol. 28:79-85. http://dx.doi.org/10.1111/j.1574- 695X.2000.tb01460.x. (Pubitemid 30184876)
47. Jiang HQ, Hoiseth SK, Harris SL, McNeil LK, Zhu D, Tan C, Scott AA, Alexander K, Mason K, Miller L, DaSilva I, Mack M, Zhao XJ, Pride MW, Andrew L, Murphy E, Hagen M, French R, Arora A, Jones TR, Jansen KU, Zlotnick GW, Anderson AS. 2010. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine 28:6086-6093. http://dx.doi.org/10.1016/j.vaccine.2010.06.083.
48. Lee AW, Vesikari T, Gilbert CL, Klopfer SO, Schödel FP, Bhuyan PK. 2011. Immunogenicity and safety of a Haemophilus influenzae B (Hib)-hepatitis B vaccine with a modified process hepatitis B component administered with concomitant pneumococcal conjugate vaccine to infants. Vaccine 29:7942-7948. http://dx.doi.org/10.1016/j.vaccine.2011.08.071.
49. Koeberling O, Giuntini S, Seubert A, Granoff DM. 2009. Meningococcal outer membrane vesicle vaccines derived from mutant strains engineered to express factor H binding proteins from antigenic variant groups 1 and 2. Clin. Vaccine Immunol. 16: 156 -162. http://dx.doi.org/10.1128/CVI.00403-08.
50. Arigita C, Luijkx T, Jiskoot W, Poelen M, Hennink WE, Crommelin DJ, Ley P, Els C, Kersten GF. 2005. Well-defined and potent liposomal meningococcal B vaccines adjuvated with LPS derivatives. Vaccine 23:5091-5098. http://dx.doi.org/10.1016/j.vaccine.2005.06.001. (Pubitemid 41318157)
51. Hoogerhout P, Donders EM, van Gaans-van den Brink JA, Kuipers B, Brugghe HF, van Unen LM, Timmermans HA, ten Hove GJ, de Jong AP, Peeters CC. 1995. Conjugates of synthetic cyclic peptides elicit bactericidal antibodies against a conformational epitope on a class 1 outer membrane protein of Neisseria meningitidis. Infect. Immun. 63:3473-3478.
52. Mosmann TR, Coffman RL. 1989. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7:145-173. http://dx.doi.org/10.1146/annurev.iy.07.040189.001045. (Pubitemid 19138011)
53. Granoff DM, Maslanka SE, Carlone GM, Plikaytis BD, Santos GF, Mokatrin A, Raff HV. 1998. A modified enzyme-linked immunosorbent assay for measurement of antibody responses to meningococcal C polysaccharide that correlate with bactericidal responses. Clin. Diagn. Lab. Immunol. 5:479-485. (Pubitemid 28342873)
54. Martin DR, Ruijne N, McCallum L, O'Hallahan J, Oster P. 2006. The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB. Clin. Vaccine Immunol. 13:486-491. http://dx.doi.org/10.1128/CVI.13.4.486-491.2006. (Pubitemid 44044834)
55. Sprong T, Ley P, Abdollahi-Roodsaz S, Joosten L, Meer Jv, Netea M, Deuren Mv. 2011. Neisseria meningitidis lipid A mutant LPSs function as LPS antagonists in humans by inhibiting TLR 4-dependent cytokine production. Innate Immun. 17:517-525. http://dx.doi.org/10.1177/1753425910383999.
56. Steeghs L, Keestra AM, van Mourik A, Uronen-Hansson H, van der Ley P, Callard R, Klein N, van Putten JP. 2008. Differential activation of human and mouse Toll-like receptor 4 by the adjuvant candidate LpxL1 of Neisseria meningitidis. Infect. Immun. 76:3801-3807. http://dx.doi.org/10.1128/IAI.00005- 08.
57. Lindberg AA, Hellerqvist CG. 1980. Rough mutants of Salmonella Typhimurium: immunochemical and structural analysis of lipopolysaccharides from rfaH mutants. J. Gen. Microbiol. 116:25-32. (Pubitemid 10137452)
58. Nagaoka K, Takahara K, Tanaka K, Yoshida H, Steinman RM, Saitoh S, Akashi-Takamura S, Miyake K, Kang YS, Park CG, Inaba K. 2005. Association of SIGNR1 with TLR4-MD-2 enhances signal transduction by recognition of LPS in gram-negative bacteria. Int. Immunol. 17:827-836. http://dx.doi.org/10.1093/ intimm/dxh264. (Pubitemid 41417950)
59. Kang YS, Yamazaki S, Iyoda T, Pack M, Bruening SA, Kim JY, Takahara K, Inaba K, Steinman RM, Park CG. 2003. SIGN-R1, a novel C-type lectin expressed by marginal zone macrophages in spleen, mediates uptake of the polysaccharide dextran. Int. Immunol. 15:177-186. http://dx.doi.org/10.1093/intimm/dxg019. (Pubitemid 36267109)
60. de Vries FP, van Der Ende A, van Putten JP, Dankert J. 1996. Invasion of primary nasopharyngeal epithelial cells by Neisseria meningitidis is controlled by phase variation of multiple surface antigens. Infect. Immun. 64:2998-3006. (Pubitemid 26256138)
61. Jennings MP, Srikhanta YN, Moxon ER, Kramer M, Poolman JT, Kuipers B, van der Ley P. 1999. The genetic basis of the phase variation repertoire of lipopolysaccharide immunotypes in Neisseria meningitidis. Microbiology 145(Pt 11):3013-3021. (Pubitemid 29535022)
62. Tritto E, Mosca F, De Gregorio E. 2009. Mechanism of action of licensed vaccine adjuvants. Vaccine 27:3331-3334. http://dx.doi.org/10.1016/j.vaccine. 2009.01.084.